Erlotinib

🧮 Dose calculator

Lung cancer (small-cell and non-small-cell) · Regimen source: FDA Erlotinib · 2.2

• • Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label. FDA Erlotinib · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Erlotinib · 8.1

  “Risk Summary Based on animal data and its mechanism of action, erlotinib can cause fetal harm when administered to a pregnant woman.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Erlotinib · 8.2

  “Advise a lactating woman not to breastfeed during treatment with erlotinib tablets and for 2 weeks after the final dose.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Erlotinib · 8.4

  “The safety and effectiveness of erlotinib in pediatric patients have not been established.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Erlotinib · 8.5

  “No overall differences in safety or efficacy were observed between subjects 65 years and older and those younger than 65.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Erlotinib · 8.3

  “Contraception Females Erlotinib can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] .”